ABSTRACT AIM: The study was aimed at elucidating the infl uence of a 3-month treatment with routine therapeutic regimens -oral hormonal contraceptives (OHC) with antiandrogenic activity (a standard combination of ethynil estradiol 35 μg plus cyproterone acetate 2 mg) in combination with insulin sensitizing agents -metformin (Group I) and rosiglitazone (Group II) on adipose tissue hormones and hypothalamic neuropeptide Y (NPY) in women with polycystic ovary syndrome. PATIENTS AND METHODS: The study included 66 overweight insulin resistant women with PCOS according to the recent ESHRE-ASRM criteria randomized into 2 age-matched therapeutic groups. RESULTS: Signifi cant decrease of leptin (Р < 0.01; Р = 0.001, resp.), resistin (Р < 0.01; Р < 0.01, resp.), tumour necrosis factor α (TNFα) (Р = 0.001; Р < 0.001, resp.), and NPY (Р < 0.05; Р < 0.001, resp.) was observed in both groups after treatment. These fi ndings were in parallel with a signifi cant decrease in the anthropometric parameters of body weight in the metformin group only. No signifi cant changes in hormonal characteristics of the groups were found except for a signifi cant decrease in androstenedione and DHEA-S (Р < 0.05) in the metformin group and in 17-OH-progesterone (Р < 0.05) in the rosiglitazone group. HDL-cholesterol rose and diastolic blood pressure fell signifi cantly (Р < 0.05) in the metformin group. CONCLUSION: Our data suggest benefi cial effects of the treatment on potential cardiovascular risk in insulin resistant PCOS women.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most common endocrine metabolic diseases, affecting up to 10% of women of reproductive age. 1 Obesity is present in 30-70% of women depending on the setting of the study and the ethnical background of the subjects, and it is characterized by central distribution of fat. 2, 3 Thus, we found overweight in 28.72% and obesity in 48.94% out of 94 women with PCOS, and in 22%, and 51%, respectively in another cohort of 142 Bulgarian patients. 4, 5 In women with PCOS, hyperinsulinemia, dyslipidemia, and/or hypertension are highly dependent on obesity which worsens all of the clinical manifestations of PCOS. 6, 7 
ORIGINAL ARTICLES

Clinical Investigations
The discovery of leptin in 1994 provoked the interest in the adipose tissue which was no longer considered as an inert tissue storing energy in the form of triglycerides, but as the greatest endocrine organ in human body. It is already known that adipocytes secrete a series of substances with local and distant effects. These are leptin, adiponectin, resistin, TNFα, omentin, visfatin, interleukin 6, etc. These hormones play an important role in metabolism, reproductive processes, cardiovascular function, and immunity. At present, there is an increasing body of evidence of high levels of atherogenic adipocytokines and low levels of adiponectin in women with PCOS that change according to variations of fat mass. 8 Endocrine function of the adipocytes is regulated mainly by nutritional status, and both these factors are integrally interweaved with the energy storing mechanism in the adipose tissue. Neuropeptide Y (NPY) is a potent orexigenic peptide synthesized in the hypothalamus whose secretion is increased in response to metabolic challenges. It is still not clear if there are consistent differences in the levels or in the effects of appetite-regulating hormones as is NPY in PCOS. 9 Routine therapeutic regimens in women with PCOS include oral hormonal contraceptive (OHC) with antiandrogenic activity alone or in combination with insulin sensitizing agents (metformin and thiazolidinediones) in populations of women with overweight and insulin resistance. 10 Both metformin and rosiglitazone are supposed to counteract unfavourable metabolic consequences of OHC and markedly potentiate its antiandrogenic activity. [11] [12] [13] Few studies have so far directly compared metformin with thiazolidinediones for the treatment of PCOS. In a report involving the comparison between metformin and rosiglitazone, it was demonstrated that they both improved ovarian function and reduced hirsutism, especially the latter drug. 14 The effect of combined treatment on adipose tissue hormones and hypothalamic neuropeptide Y (NPY) in PCOS is under investigation.
AIM
The AIM of the study was to elucidate the infl uence of a 3-month treatment with routine therapeutic regimens-OHC with antiandrogenic activity (Diane 35 -a standard combination of ethynil estradiol 35 μg plus cyproterone acetate 2 mg) in combination with the insulin sensitizing agents -metformin and rosiglitazone on adipose tissue hormones and hypothalamic NPY in overweight insulin resistant PCOS women.
PATIENTS AND METHODS
The study comprised 66 overweight insulin resistant women with PCOS randomized into 2 age-matched therapeutic groups (mean age 23.58 ± 4.17 yrs; 23.25 ± 4.95 yrs, resp., Р > 0.05). Group I (n = 32) was treated with Diane 35 and metformin (1275-1500 mg daily); Group II (n = 34) was treated with Diane 35 and rosiglitazone (4 mg daily) for 3 months. The diagnosis of PCOS was defi ned according to the consensus criteria for PCOS accepted in May 2003, Rotterdam: oligo-or anovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries. The diagnosis was made in the presence of two out of the three mentioned criteria. 15 None of the subjects had previously been diagnosed as having PCOS or had been receiving hormonal treatment for at least 3 months prior to their evaluation. Homeostasis model of insulin resistance (HOMA-IR) was calculated as immune reactive insulin (IRI) x blood glucose/22.5. The cutoff of 2.5 for HOMA-IR and/or >100 μIU/ml for IRI during a standard oral glucose tolerance test (oGTT) were used for determining insulin resistance.
A comprehensive set of hormonal tests was performed in all study subjects in order to exclude other endocrine pathology such as thyroid dysfunction, prolactinoma, Cushing's syndrome, congenital or non-classical adrenal hyperplasia, hormone secreting tumours, diabetes mellitus, and pregnancy. Waist circumference was measured at the smallest part of the waist and hip circumference was measured at the widest level of the buttocks, and the average of two measurements was calculated. The amount and percentage of the adipose tissue, fat free tissues (FFT) and total body water (TBW) were determined by bioimpedance method using Tanita TBF-300M body composition analyzer.
Blood samples were collected from all participants in early morning at fasting stage for determination of biochemical and hormonal parameters. All laboratory tests were performed in the early follicular phase (days 1-5) of spontaneous bleeding or withdrawal bleeding. Blood samples for hormone analysis were taken in the morning at 08:00 h after an overnight fast and centrifuged immediately. The serum was separated and frozen at -77°C until assayed.
The following serum levels were determined at baseline and after 3 months of treatment: leptin, resistin, TNFα, NPY (primary outcomes); total testosterone (T), androstenedione, dehydroepiandrosterone sulphate (DHEAS), 17-OH progesterone, estradiol (E2), FSH, LH (LH/RH ratio was calculated), prolactin, glucose and IRI during an oGTT, total cholesterol, HDL-cholesterol, triglycerides, ASAT, ALAT, GGTP (secondary outcomes).
Leptin was determined by means of a solidphase immunoenzyme assay (Human) ELISA (commercial kit of DRG, Germany) with the following characteristics: sensitivity -0.2 ng/ml; inter assay variation, CV% < 5.4; intra assay variation, CV% < 8.7%; correlation with RIA, r = 0.95. Resistin was determined using a commercial kit of PHOENIX PHARMACEUTICAL INC, USA based on the principle of a "competitive" solidphase immunoenzyme method (Human) EIA with the following characteristics: sensitivity -1.16 ng/ ml; inter assay variation, CV% < 5.0; intra assay variation, CV% < 14. TNFα was determined using a commercial kit of DRG, Germany by means of a solid-phase immunoenzyme method of greater sensitivity (Human) ELISA with the following characteristics: sensitivity -3.0 pg/ml; inter assay variation, СV% < 5.2; intra assay variation, СV% < 10.0. NPY was determined using a commercial kit of PHOENIX PHARMACEUTICAL INC, USA based on the principle of a "competitive" solidphase immunoenzyme method (Human) EIA with the following characteristics: sensitivity -0.21 ng/ ml; inter assay variation, CV% < 5.0; intra assay variation, CV% < 14. Insulin was tested using a commercial kit for quantitative determination of immunoreactive insulin on the basis of microparticular immunoenzyme analysis (MEIA) by means of AxSYM system (ABBOTT, USA) with the following characteristics: sensitivity ≤ 0.8 μIU/ ml; inter assay variation, СV% < 2.9; intra assay variation, СV% < 5.3. The hormonal tests including T, androstenedione, DHEA-S, 17-OH progesterone, E2, LH, FSH, prolactin, were performed on an Ax-SYM TM System (Abbott Diagnostics, Abbott Park, Il, USA) using commercial kits. Serum levels of glucose were determined by standard GOD-POD method. The area under the curve (AUC) for glucose and insulin during the oGTT was calculated using the trapezoid method. Total cholesterol was determined by ChOD, PAP, triglycerides by GPO, PAP, and HDL-cholesterol by MgSO 4 -dextran SO 4 praecipitation, Schneiders Analysers; Netherlands test; Delta Kone Autoanalyser. LDL-cholesterol was calculated using Fridewald formula. Liver enzymes (ASAT, ALAT, GGTP) were determined by routine laboratory analyses.
The statistical analysis was performed by SPSS version 12.0.1 (SPSS, Inc., Chicago, IL, USA). The distribution of the data was tested using the Kolmogorov-Smirnov test for normality. Correla- Comparison between groups was performed by an unpaired t-test for normally distributed data. The results are presented as mean ± standard deviation (SD). Results were considered significant if P < 0.05. All P-values are two-tailed.
The main baseline characteristics of the groups are presented in Tables 1-3 .
RESULTS
The two studied groups were age and weight matched that forms a part of the study design. There was no signifi cant difference in the body weight, BMI, waist circumference WHR and parameters of body fat distribution between the two groups of PCOS women (Table 1) . No signifi cant differences were found in the baseline hormonal ( Table 2, Table 3 ) After the 3-month treatment leptin, resistin, TNFα and NPY signifi cantly decreased in both treatment groups. The changes were more pronounced in the rosiglitazone group (Table 3) . The signifi cant correlations of NPY, and adipose tissue hormones with the main clinical, hormonal and biochemical parameters at baseline are shown on Table 5 .
TREATMENT GROUP I (DIANE 35+METFORMIN)
In Group I body weight, BMI, amount of fats and waist circumference decreased signifi cantly (Р = 0.009; Р = 0.009, Р = 0.032, Р = 0.019, resp.) after treatment. All androgens tended to decrease but the changes reached signifi cance only for androstenedione and DHEA-S (Р = 0.017, Р = 0.042, resp). LH (LH/FSH ratio, resp.) showed a tendency to decrease, while FSH, E2 and prolactin did not change considerably. All parameters of glucose and insulin during oGTT and HOMA-IR did not change. The marked variations in insulin may contribute to the lack of signifi cant dynamics of the associated variables. A positive impact on lipid profi le is observed -HDL-cholesterol increased signifi cantly (Р = 0.032). Hepatic enzymes did not change signifi cantly (ASAT-19.71 ± 6.85; 17.93 ± 4.48, resp.; ALAT-20.36 ± 6.77; 19.57 ± 6.35, resp. GGTP-22.10 ± 12.49; 22.45 ± 10.53, resp., P > 0.05). Diastolic blood pressure fell signifi cantly from 76.54 ± 10.28 mm Hg to 72.69 ± 8.57 mm Hg (Р = 0.035) while systolic blood pressure did not show signifi cant dynamics (119.23 ± 17.06 mm Hg; 116.15 ± 14.46 mm Hg, resp.). In this group the signifi cant correlations between leptin and parameters of body weight remained similar after treatment. In addition, TNFα showed positive correlations with weight, BMI, waist circumference, percentage of fat tissue and fat mass in kg, (r = 0.669, r = 0.629, r = 0.612, r = 0.585, r = 0.671, resp., p < 0.01), total and LDL-cholesterol (r = 0.501, p < 0.05; r = 0.586, resp., p < 0.01), and a negative correlation with HDL-cholesterol (r = -0.516, p < 0.05). Diastolic blood pressure showed negative correlations with leptin and NPY (r = -0.511, r = -0.515, resp., p < 0.05). Interestingly, blood glucose at the 180 -th min. during the oGTT showed signifi cant positive correlations with leptin, TNFα, and NPY (r = 0.554, r = 0.505, r = 0.487, resp., p < 0.05), and insulin at the 120 -th min. during the oGTT showed signifi cant negative correlation with NPY (r = -0.478, p < 0.05). .), nor diastolic blood pressure showed dignifi cant changes, but there was a trend towards decrease for the latter (79.14 ± 9.82 mm Hg; 75.88 ± 9.56 mm Hg, resp.), similarly to the fi ndings in Group I. As in Group I, positive correlation of the anthropometric parameters with leptin persisted. Leptin showed signifi cant positive correlation with basal insulin, HOMA-IR, insulin at the 60 -th min, and AUCins (r = 0.698, r = 0.681, resp., p < 0.01; r = 0.451, r = 0.454, resp. p < 0.05), and negative one -with HDL-cholesterol (r = -0.555, p < 0.05). TNFα showed positive correlation with weight, BMI and waist circumference ((r = 0.508, r = 0.513, r = 0.461, resp., p < 0.05), as in Group 1, but also with the WHR (r = 0.448, p < 0.05) and only with the fat mass in kg (r = 0.492, p < 0.05), but not with the percentage of fat. In addition, there was a positive correlation of TNFα with glucose and insulin at the 60 -th min. during the oGTT (r = 0.502; r = 0.480, resp., p < 0.05), and a negative one with HDL-cholesterol (r = -0.483, p < 0.05).
DISCUSSION
PCOS is considered to be the most common endocrine disorder in women during their reproductive years. 1 Since 1980, PCOS has been strongly associated with the presence of insulin resistance (IR) and secondary hyperinsulinemia, mainly but not exclusively, in obese women. The prevalence of IR among these women varies according to the sensitivity and specifi city of the assays used and the population of women studied. Previous studies have demonstrated that secondary hyperinsulinemia is the key factor responsible for the hyperandrogenism characteristic of the syndrome 16, 17 , which is attributed to an increased stimulation of the activity of the cytochrome P450c 17α in the ovary 18 . Hyperinsulinemia also decreases the circulating concentrations of SHBG and contributes to greater concentrations of free androgens in the blood. 18 Women with PCOS and IR have a greater risk for carbohydrate intolerance and type 2 diabetes mellitus (DM), dyslipidemia, arterial hypertension, coagulation disorders induced by endothelial dysfunction, and cardiovascular disease. 6, 7, 19, 20 Because IR is a cardinal feature of PCOS, one therapeutic approach is to use drugs to improve insulin sensitivity and ovarian function. 11 Therapies that decrease insulin concentrations can be effective not only in obese but also in normal-weight PCOS women. Metformin, a biguanide class drug, has become the most widely used drug to treat women with IR and PCOS. [10] [11] [12] [13] [14] Other drugs include thiazolidinediones (TZD) like rosiglitazone and pioglitazone, and most studies using these drugs in women with PCOS did not report serious adverse reactions. 11, 21, 22 Some studies have demonstrated an increase in ovulatory cycles in PCOS women when insulin sensitivity is increased by metformin or a thiazolodinedione. [23] [24] [25] In short-term (6-month) studies, insulin sensitivity and androgen excess improved in women with PCOS treated either with metformin (2500 mg/day) or pioglitazone. 26, 27 In a report involving the comparison between metformin and rosiglitazone, it was demonstrated that they both improved ovarian function and reduced hirsutism, especially the latter drug. 28 Oral contraceptive pills have been the traditional medical therapy for the long-term treatment of PCOS in order to regularize menses, to improve hirsutism and/or acne by reducing ovarian androgen production and to provide endometrial protection. The most clinically effi cacious approach using oral contraceptives in PCOS women can be obtained combining estrogen with cyproterone acetate, which has both progestagen and anti-androgen activity and also induces hepatic metabolism and increases testosterone clearance. 29, 30 In combination with estrogens, cyproterone acetate is almost as effective as GnRH agonist at suppressing serum LH and T, and the clinical effi cacy of the two treatments are equivalent. 31 The combination of 35 μg ethynil oeastradiol and 2 mg cyproterone acetate (Diane 35) is one of the most widely prescribed OHC in Europe for treatment of PCOS in women who do not desire conception with effective and relatively rapid amelioration of menstrual abnormalities and clinical signs of hyperandrogenism. 32 In our study we observed a decrease of all androgens, but the changes reached signifi cance for androstenedione and DHEA-S in Group I, and 17-OH progesterone in Group II. LH and LH/FSH also showed a trend to decrease, but possibly due to the inter-group variations this was not signifi cant. Adding insulin sensitizers to OHC could neutralize possible unfavourable metabolic consequences of monotherapy with the latter and to provide additional benefi cial effects on reproductive and hormonal disturbances. No negative infl uence on carbohydrate and lipids metabolism was observed in our patients, even there was a positive effect on HDL-cholesterol in Group I.
Adipose tissue is now considered as the most abundant endocrine organ in the body. Adiposity is closely linked to insulin resistance, diabetes, and cardiovascular disease through different mechanisms including production and secretion of several hormones, cytokines, and other molecules; defects in insulin signalling; low-grade chronic infl ammation; and dysfunctional steroidogenesis. Abdominal adiposity or obesity are present in most women with PCOS, adversely infl uencing both the metabolic and reproductive phenotype of the syndrome. 32, 33 There are a series of abnormalities in the adipose tissue hormones in women with PCOS, some of which are due to obesity but others that could be disease specifi c. 33, 34 At present there is an increasing body of evidence of high levels of leptin and other atherogenic adipocytokines and low levels of adiponectin in women with PCOS that change according to variations of fat mass 8, 34 , but the data are somewhat controversial. We found a signifi cant decrease in the atherogenic adipocytokines leptin, resistin and TNFα after treatment.
Some reports have shown that women with PCOS have higher circulating concentrations of leptin as compared with BMI-matched controls, in contrast with other studies on both adolescent and adult subjects with PCOS that show that the concentrations of leptin in PCOS are not signifi cantly different from those of controls when BMI is used as covariate. 35 However, a report on south Indian women demonstrated that circulating concentrations of leptin were higher in normal-weight and obese subjects with PCOS than in controls. 36 The role of hyperleptinemia in women with PCOS is not clear yet, and the possibility exists that women with PCOS are leptin resistant. 9, 34 Hyperleptinemia seems to be inversely related to the degree of fertility in women with PCOS and elevated leptin levels may contribute to the lack of follicular maturation in PCOS. 37 Resistin is a positive marker of coronary atherosclerosis. Its levels were found to be higher in patients with PCOS than in age-and BMI-matched controls. 35 Given the poor relation between resistin and insulin resistance in humans, however, it seems unlikely that resistin is responsible for the increased insulin resistance in our PCOS patients. Nevertheless, it may play a contributory role in the proinfl ammatory state 38 , associated with metabolic syndrome, and the fact that its levels decreased with treatment is considered benefi cial in the terms of potential cardiovascular risk in overweight insulin resistant women with PCOS.
One of the mechanisms of insulin resistance in obesity may be inhibition of insulin signalling by TNFα 39 , furthermore, TNFα decreases adipocyte secretion of adiponectin and suppresses Glut-4 glucose transporters and insulin receptors 40 . TNFα levels were found elevated in both lean and obese PCOS by Li et al. 41 Similarly to that of resistin, the decrease of TNFα after treatment should be benefi cial in terms of cardiovascular risk.
Increased plasma NPY levels were found in both obese and non-obese women with PCOS, as compared to controls, independent of body weight increase. 42 Gennarelli et al. 43 reported similar NPY levels at rest in PCOS and normo-ovulatory women, but an impaired NPY response to hypoglycemia in PCOS women. Clinical evidence suggests that NPY exerts primarily an inhibitory effect on the hypothalamic-pituitary-ovarian axis. 44 It is known that NPY stimulates appetite leading to hyperphagia, increase of body fat, decrease of thermogenesis and suppression of sympathetic activity, thus it serves as main regulator of food intake, body weight and energy consumption. 44 So, the decrease observed in our patients after treatment should be benefi cial in terms of ameliorating ovarian function and prevention of weight gain.
In our study leptin and TNFα were in signifi cant positive correlation with weight, BMI and anthropometric parameters. The hyperglycaemic response after glucose load and HDL-cholesterol were also associated with these two adipocytokines. Basal hyperinsilinaemia and markers of insulin resistance in this cohort of PCOS were associated with leptin and the postload hyperinsulinaemia was associated with NPY. No correlations were found between adipose tissue hormones and androgens, there was a negative one between androstenedione and NPY. Resistin did not show signifi cant correlations with any of the clinical and biochemical characteristics of PCOS.
Interventions that infl uence reproductive and metabolic function in PCOS may also affect levels of the adipose tissue hormones and regulators of appetite, such as NPY. It has been postulated that some of the effects of insulin sensitizing agents in PCOS may be mediated through changes in adipocytokines levels. In our study the serum concentrations of NPY and all investigated adipocytokines decreased significantly after treatment in both groups. The data in the literature about changes of adipocytokines after treatment of PCOS women with OHC in combination with insulin sensitizers are scanty and we could not fi nd studies with similar design to compare our data. Thus, monotherapy with rosiglitazone (8 mg daily for 4 months) had a signifi cant effect on plasma adipocytokines levels, decreasing resistin levels in overweight women with PCOS. 45 But Jakubowska et al. did not fi nd changes in resistin levels in obese PCOS women after 3 and 6 months treatment with rosiglitazone (4 mg daily). 46 Lewandowski et al. 47 reported that there was no correlation between the serum resistin and adiponectin levels, insulin resistance, lipids and serum androgen levels in patients with PCOS which is similar to our data.
The change of NPY and adipocytokines was associated with weight loss only in the metformin group that is an expected effect of the drug and in conformity with other studies. Thus, metformin decreased BMI signifi cantly in the pioneering observational study of Velazquez et al. 48 Recently, a meta-analysis of 14 trials including 649 women and comparing metformin and placebo with or without lifestyle modifi cation showed a statistically signifi cant decrease in BMI after treatment. 49 It is proven that in PCOS weight loss improves insulin sensitivity, diminished insulin levels, decreased androgens (testosterone), and increased ovulation rates. 50, 51 We also observed decrease in androgens -androstenedione and DHEA-S fell signifi cantly and there was a non signifi cant diminution in total testosterone. No signifi cant changes in glucose and insulin levels at fasting state and after oGTT, as well as in HOMA-IR were observed. Our results are similar to those of Elter, et al, and Cibula, et al. 52, 53 A relatively short duration of the treatment is a limitation of the study, conclusions can be drawn after a longer period of follow-up of the patients.
However, recent and contradictory observational evidence has raised the concern that oral contraception may reduce insulin sensitivity and glucose tolerance in PCOS women. A recent review by Costello et al. 54 , comparing metformin versus oral contraception in PCOS, did not show signifi cant difference between the two therapies in reducing fasting glucose or total cholesterol concentrations. Moreover, fasting insulin and triglycerides concentrations did not increase after oral contraception treatment. Thus, the limited evidence to date does not show adverse metabolic risk with the use of oral contraception. We also did not fi nd unfavourable metabolic effects when Diane 35 was used in combination with insulin sensitizers, there was a trend to lower basal and postload insulinaemia and even a rise in HDL-cholesterol in the metformin group. No adverse effects were observed during the whole treatment period.
CONCLUSIONS
In conclusion, the present data suggest that a 3-month treatment with metformin and rosiglitazone, added to OHC (a standard combination of ethynil oeastradiol 35 μg plus cyproterone acetate 2 mg) in overweight insulin resistant women with PCOS resulted in decrease of the serum concentrations of NPY and atherogenic adipocytokines (leptin, resistin, and TNFα) that may have benefi cial effects in the future prevention of atherosclerosis and cardiovascular diseases in this risk cohort of young women. HDL-elevation and diastolic blood pressure diminution confi rm this suggestion. Having in mind that the decrease in NPY and adipocytokines was not in parallel with changes in body weight and composition in the rosiglitazone group and is associated with only slight and non signifi cant infl uence on hyperinsulinaemia, resp. insulin resistance, additional direct adipose tissue and/or disease specifi c effects of the treatment may come into consideration that needs further elucidation.
